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Abstract
The primary aim of this study was to measure HIV-1 persistence following combination anti-
retroviral therapy (cART) in infants and children. Peripheral blood mononuclear cell (PBMC)
HIV-1 DNA was quantified prior to and after 1 year of cART in 30 children, stratified by time
of initiation (early, age <3 months, ET; late, age >3 months-2 years, LT). Pre-therapy PBMC
HIV-1 DNA levels correlated with pre-therapy plasma HIV-1 levels (r = 0.59, p<0.001),
remaining statistically significant (p = 0.002) after adjustment for prior perinatal antiretroviral
exposure and age at cART initiation. PBMC HIV-1 DNA declined significantly after 1 year of
cART (Overall: -0.91±0.08 log10 copies per million PBMC, p<0.001; ET: -1.04±0.11 log10
DNA copies per million PBMC, p<0.001; LT: -0.74 ±0.13 log10 DNA copies per million
PBMC, p<0.001) but rates of decline did not differ significantly between ET and LT. HIV-1
replication exposure over the first 12 months of cART, estimated as area-under-the-curve
(AUC) of circulating plasma HIV-1 RNA levels, was significantly associated with PBMC
HIV-1 DNA at one year (r = 0.51, p = 0.004). In 21 children with sustained virologic suppres-
sion after 1 year of cART, PBMC HIV-1 DNA levels continued to decline between years 1
and 4 (slope -0.21 log10 DNA copies per million PBMC per year); decline slopes did not dif-
fer significantly between ET and LT. PBMC HIV-1 DNA levels at 1 year and 4 years of cART
correlated with age at cART initiation (1 year: p = 0.04; 4 years: p = 0.03) and age at viro-
logic control (1 and 4 years, p = 0.02). Altogether, these data indicate that reducing expo-
sure to HIV-1 replication and younger age at cART initiation are associated with lower HIV-
1 DNA levels at and after one year of age, supporting the concept that HIV-1 diagnosis and
cART initiation in infants should occur as early as possible.
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Introduction
Control of HIV-1 replication following the initiation of combination antiretroviral therapy
(cART) in the first few months following birth preserves CD4+ T cell counts and general
immune function and prevents HIV-1 associated disease progression in infants [1, 2]. Early
combination antiretroviral therapy can also markedly reduce HIV-1 associated mortality [3].
Current guidelines [4, 5] thus recommend early infant diagnosis and the immediate initiation
of cART in all HIV-1 infected infants under 12 months of age.
While cART may control HIV-1 replication to the point that plasma HIV-1 RNA levels
are undetectable by routine and ultrasensitive assays, HIV-1 DNA remains detectable in cir-
culating CD4+ T cells. The observation that most children, including those with stable, long-
term suppression of HIV-1 replication on cART, experience a rebound in viral replication
within weeks of discontinuing therapy [6, 7] is compatible with the notion that at least some
of the detectable cell-associated HIV-1 DNA is replication-competent; long-lived memory
CD4+ T cells that harbor replication-competent HIV-1 (“latent reservoir”) serve as a barrier
to cure [8, 9].
Low circulating levels of HIV-1 DNA and smaller latent reservoir size have been measured
in adults who have persistently controlled HIV-1 replication off cART following treatment in
primary infection [10, 11]. PBMC HIV-1 DNA levels can be readily measured using the small
blood volumes available from infants while in vitro viral outgrowth assays that measure the
fraction of replication-competent HIV-1 require relatively large blood volumes (Reviewed in
[8]). Cross-sectional studies have demonstrated lower levels of circulating HIV-1 DNA in chil-
dren who suppressed HIV-1 replication prior to one year of age than after one year of age [12–
14]. However, data quantifying HIV-1 persistence in children before and immediately follow-
ing early cART are limited. We undertook this study to quantify PBMC HIV-1 DNA levels
before and up to four years following early cART in children, with the specific goal of examin-
ing the relationships between circulating PBMCHIV-1 DNA levels to the timing of cART initi-
ation and the duration of viremic exposure over the first year of treatment.
Materials and Methods
Study Cohort
The study cohort included 30 HIV-1 infected children (Table 1), stratified by timing of cART
initiation (early therapy,<3 months of age, ET; late therapy,>3 months to 2 years, LT), for
whom sufficient cryopreserved PBMC were available to measure HIV-1 DNA prior to and
after 1 year of cART. Twenty-eight children received cART through an open-label, Phase I/II
clinical trial (Pediatric AIDS Clinical Trials Group Protocol, PACTG 356 (NCT00000872, [6])
and two were treated by open prescription. HIV-1 DNA levels were measured yearly thereafter
up to 4 years following cART initiation in 21 children who achieved plasma HIV-1 RNA levels
of<400 copies/ml by 48 weeks of therapy and who sustained plasma HIV-1 RNA< 50 copies/
ml thereafter (“virologic responders”). Children were excluded from analyses when plasma
HIV-1 RNA was again detected at levels>50 copies/ml. Institutional Review Boards at the
University of Massachusetts Medical School and at the clinical sites participating in PACTG
356 approved this study. Signed informed consent was obtained from all study participants’
guardians.
Quantitation of circulating HIV-1 RNA and total HIV-1 DNA in PBMC
Blood collected in tubes containing either acid citrate dextrose or EDTA (Becton-Dickinson,
Mountainview, CA) was processed to collect plasma and to prepare PBMC pellets using Ficoll-
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Paque (Pharmacia Fine Chemicals, Piscataway, NJ) density gradient separation [15]. Plasma
HIV-1 RNA load was measured using either the Roche Standard (LOD<400 copies/ml) or
UltraSensitive (LOD<50 copies/ml) AMPLICOR HIV-1 MONITOR kits Version 1.5 (Roche
Diagnostics, Indianapolis, IN).
Following lysis of PBMC pellets, HIV-1 DNA copy numbers in the cell lysates were quanti-
fied using the Amplicor HIV-1 DNA PCR assay version 1.5 (Roche Diagnostics, Branchburg,
NJ) in a limiting dilution assay (LDA) format with endpoint calculations using the “Quality”
computer program, as previously described [15]. Lysates of HIV-1 uninfected PBMC spiked
with standardized numbers of 8E5 T cells (each containing a single copy of HIV-1 DNA) were
used to determine the lower limit of endpoint detection (PCR-positive reaction) of the assay (2
copies of HIV-1 DNA per PCR), which is comparable to the detection limits reported using
droplet digital PCR and real-time qPCR [7, 10, 16]. DNA levels were expressed as copies per
106 PBMC with a detection limit of ~3–5 copies per 106 PBMC.
Statistical Analyses
Analyses used the software Stata (v13, StataCorp.) and GraphPad Prism version 6.05 for Win-
dows, (GraphPad Software, San Diego California USA, www.graphpad.com). Correlations for
log-transformed data were calculated using Pearson (r); for non-transformed data, Spearman
rho was calculated. Generalized linear models (logistic regression for binary outcomes and
ordinary least squares regression or continuous data) were fit to test for association with
response status or plasma HIV-1 RNA copy numbers. Testing for association between concur-
rent pre-therapy plasma HIV-1 RNA and PBMC HIV-1 DNA values used linear regression
models correcting for potentially confounding covariates. We quantified the degree of exposure
to viral replication over the first 12 months of therapy by calculating the area-under-the-curve
(AUC) of the circulating plasma HIV-1 RNA levels using the trapezoidal rule. The AUC esti-
mation was limited to 1 year after treatment initiation because sampling after one year was less
frequent than prior to 1 year. Linear regression models were used to predict one-year HIV-1
DNA values from the HIV-1 RNA AUC calculated from the previous 12 months, adjusting for
potentially confounding covariates. Repeated PBMC HIV-1 DNA levels collected longitudi-
nally were tested with linear mixed-regression models to estimate relative decline rates in ET
and LT treated groups. The primary test of statistical significance is the time by treatment
group interaction, which tests for differences in the shape of treatment-specific response
Table 1. Study Cohort: Pre-therapy Viral Load, CD4%, and Therapeutic Regimensa.
Cohort N Age (mos) log10 Plasma HIV-1 RNA (copies/ml) log10 HIV-1 DNA (copies/million PBMCs) CD4% Therapeutic Regimens
All subjects 30 2.9 (1.6–6.5) 5.3 (4.9–5.6) 3.4 (2.8–3.9) 40 (26–47) 19 (2 NRTIs + 1 NNRTI + 1 PI)
9 (3 NRTIs + 1 NNRTI)
2 (2 NRTIs + 1 NNRTI)
ET Responders b 13 1.9 (1.4–2.3) 5.3 (5.1–5.6) 3.0 (2.7–3.4) 36 (28–57) 10 (2 NRTIs + 1 NNRTI + 1 PI)
2 (3 NRTIs + 1 NNRTI
1 (2 NRTIs + 1 NNRTI)
LT Responders b 8 9.6 (5.7–13.3) 4.8 (3.6–5.7) 3.7 (3.0–3.9) 38 (28–43) 5 (2 NRTIs + 1 NNRTI + 1 PI)
2 (3 NRTIs + 1 NNRTI)
1 (2 NRTIs + 1 NNRTI)
a Values are provided as medians with 25th and 75th percentiles (IQR).
b Responders were deﬁned as study subjects who achieved a viral load of <400 copies/ml by 48 weeks of cART therapy and whose peripheral blood HIV-
1 RNA levels remained under assay detection limits through 4 years of cART.
doi:10.1371/journal.pone.0154391.t001
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curves. Additional post-estimation contrasts were used to compare group-means between
groups at specific time points, the rate of decline from year 0 to 1 between groups, and further
declines from one year to year 4 using reverse adjacent contrasts. All statistical tests were two-
sided and p<0.05 was considered statistically significant.
Results
Rapid decline in PBMC HIV-1 DNA levels over the first year of cART
Thirty children, aged 1 month to 19 months, stratified by age at initiation of therapy (< 3
months, ET or 3 months-2 years, LT) were included in the study. Overall, the median age of
children at cART initiation was 2.9 months and the median pre-therapy plasma HIV-1 RNA
level was 5.3 log10 copies/ml (IQR: 4.9 to 5.6 copies/ml). The median pre-therapy PBMC HIV-
1 DNA level was 3.4 log10 copies/ million PBMC (IQR: 2.8–3.9 log10 copies/ million PBMC).
Pre-therapy PBMC HIV-1 DNA levels did not differ significantly between ET (median, 3.3
log10 copies/ million PBMC, IQR: 2.8–3.6 log10 copies/ million PBMC) and LT (median, 3.7
log10 copies/ million PBMC, IQR: 3.4–3.9 log10 copies/ million PBMC) children. Pre-therapy
PBMC HIV-1 log10 DNA levels correlated with pre-therapy plasma log10 HIV-1 RNA levels
(r = 0.59, p<0.001), remaining statistically significant (p = 0.002) after adjustment for prior
antiretroviral exposure and age at cART initiation using linear regression.
Over the first year of cART, PBMC HIV-1 DNA levels declined significantly (-0.91±0.08
log10 copies/ million PBMC, p<0.001) from pre-therapy levels. The estimated slopes for
decline were -1.04±0.11 log10 DNA copies/ million PBMC in ET (p<0.001) and -0.74±0.13
log10 DNA copies/ million PBMC in LT (p<0.001); the slopes of decline did not differ signifi-
cantly between ET and LT (p = 0.07) children.
Plasma HIV-1 RNA values were intensively monitored over the first year of cART and were
used to calculate an area under the curve (AUC) as a more refined measure of exposure to viral
replication. A median of 15 HIV-1 RNA values (range 11–18) were available through 12
months for each study subject and were included in the AUC calculations. Plasma HIV-1 RNA
AUC log10 was significantly associated with PBMC HIV-1 log10 DNA levels at one year
(r = 0.51, p = 0.004, Fig 1).
Continued decline in PBMC HIV-1 DNA levels after one year of cART in
virologic responders
Twenty-one children (13 ET, 8 LT) met the criteria for virologic suppression at one year and
continued on cART (Table 1). There were no significant differences in pre-therapy plasma
HIV-1 RNA levels, PBMC HIV-1 DNA levels, %CD4, and exposure to antiretroviral therapies
between virologic responders and non-responders (data not shown). Pre-therapy plasma HIV-
1 RNA levels in ET and LT responder children (median 5.3 in ET versus 4.8 log10 copies/ml in
LT children; Table 1) and pre-therapy PBMC HIV-1 DNA levels (median 3.0 and 3.7 log10
copies/million PBMC, respectively; Table 1) did not differ significantly.
In 13 ET responder children, plasma HIV-1 RNA levels fell to<400 copies/ml at a median
of 8 weeks after cART initiation (IQR: 8–12 weeks); median age at viral suppression was 4.2
months (IQR: 3.4–4.7 months). In 8 LT responder children, plasma HIV-1 RNA fell to<400
copies/ml at median 10 weeks after cART initiation (IQR: 3–12 weeks; not significant com-
pared to ET); median age at viral suppression was 11.4 months (IQR: 8.4–15 months). In all 13
ET responder children, viral suppression was accompanied by loss of HIV-specific antibodies
on enzyme-linked immunosorbent assay (ELISA) by 18 months of age; all 8 LT children
remained HIV-1 seropositive by ELISA (data not shown).
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PBMC HIV-1 DNA levels at years 1 and 4 were correlated with age at cART initiation (year
1: Spearman r = 0.45, p = 0.04; year 4: Spearman r = 0.57, p = 0.03) and age at which HIV-1
plasma HIV-1 RNA fell to<400 copies/ml (year 1: Spearman r = 0.49, p = 0.02; year 4: Spear-
man r = 0.61, p = 0.02) in responder children. In ET responder children, pre-therapy PBMC
HIV-1 log10 DNA levels were significantly correlated with PBMC HIV-1 log10 DNA levels at
year 1 (r = 0.87, p<0.001), 2 (r = 0.65, p = 0.02); and 4 years of cART (r = 0.85, p = 0.002); in
LT responder children, pre-therapy PBMC HIV-1 log10 DNA levels were significantly corre-
lated with PBMC HIV-1 log10 DNA levels at year 1 (r = 0.83, p = 0.01) and year 2 (r = 0.76,
p = 0.03), but not at 4 years of cART (r = 0.86, p = 0.052).
Declines in PBMC HIV-1 DNA levels were observed in ET and LT responder children at 1
year of cART, with calculated slopes of -1.03±0.12 log10 DNA copies/million PBMC in ET
(p<0.001) and 0.82±0.16 log10 DNA copies/million PBMC in LT (p<0.001); slopes of decline
did not differ significantly between ET and LT (p = 0.3) and the absolute log10 DNA levels
were not different in ET and LT responder children at 1 year of cART (p = 0.08). PBMC HIV-1
DNA levels continued to decline in years 1 through 4 in both the ET responder and LT
responder children (slopes -0.21±0.05 log10 DNA copies/million PBMC per year in ET,
p<0.001; -0.21±0.06 log10 DNA copies/million PBMC per year in LT p<0.001); again, the
Fig 1. Exposure to HIV-1 replication and PBMCHIV-1 DNA levels one year following cART. The
estimated 12 month AUC was significantly positively associated with HIV-1 DNA levels at one year (r = 0.51,
p = 0.004).
doi:10.1371/journal.pone.0154391.g001
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slopes of decline (p = 0.9) and year 4 PBMC HIV-1 DNA levels (p = 0.06) did not differ signifi-
cantly between ET and LT children (Fig 2).
Discussion
This study is among the first to quantify PBMC HIV-1 DNA levels in young children and to
our knowledge, the first to precisely define the relationship between circulating levels of total
PBMC HIV-1 DNA and duration of exposure to HIV-1 replication over the first year following
cART initiation. Serial measurement of PBMC HIV-1 DNA levels in children with sustained
virologic response allowed for the evaluation of continued decay of PBMC HIV-1 DNA levels
up to 4 years following cART.
High levels of total PBMC HIV-1 DNA (median 3.4 log10 copies/million PBMC) were
detected in all children prior to therapy. While our HIV-1 DNA quantification assay differed
from those used in other recent studies, PBMC HIV-1 DNA levels measured in this study prior
to therapy and at 1 year of cART were remarkably similar to those in 14 infants reported by
Uprety et al using droplet digital PCR [16].
Pre-therapy HIV-1 DNA levels correlated with plasma HIV-1 RNA levels and a steep
decline in PBMC HIV-1 DNA levels (median -0.91 log10 DNA copies/million PBMC) was
observed over the first year of treatment. In children who achieved and maintained control of
HIV-1 replication, the decline in PBMC HIV-1 DNA levels over the first year of cART (median
slope -1.03 and -0.82 log10 DNA copies/million PBMC for ET and LT respectively) was greater
than that measured after 1 year (median slope -0.21 and -0.21 log10 DNA copies/million
PBMC for ET and LT respectively). The decline in PBMC HIV-1 DNA levels over the first year
of cART were similar in magnitude to those reported over the first year of cART in adults
treated within two months of infection [10, 17], and, more recently, in a small group of early-
treated children [16]. These early changes in cell-associated HIV-1 DNA levels over the first
year of cART likely reflect a reduction in new rounds of infection along with clearance of pro-
ductively infected CD4+ T cells containing integrated HIV-1 DNA.
Continued measurement of PBMC HIV-1 DNA levels was conducted in a cohort of chil-
dren (“responders”) with sustained plasma HIV-1 RNA< 50 copies/ml, suggesting near com-
plete inhibition of HIV-1 replication. Moreover, all ET responder children seroreverted after
18 months, which has been shown to be a marker for effective early control of HIV-1 replica-
tion [2, 18] that correlates with low circulating HIV-1 DNA levels in older children [12]. Total
PBMC HIV-1 DNA levels continued to decline through four years in both ET and LT
responder children. This differs from the reported stability of PBMC HIV-1 DNA levels in chil-
dren between one and two years of cART in a recent study [16]. Of note, 56% of infants in their
study had intermittently detectable HIV-1 RNA in their plasma over the course of the study,
suggesting ongoing viral replication or production from long-lived cells with integrated
genomes.
Pre-therapy PBMC HIV-1 DNA levels did not differ significantly in ET and LT responder
children. After four years of cART, total HIV-1 DNA levels trended lower in ET responders
than in LT responders, but the study lacked sufficient power to detect differences between the
groups. However, our finding that PBMC HIV-1 DNA levels at 1 and 4 years of cART were sig-
nificantly correlated with age at cART initiation and age at virologic control is consistent with
recent reports from two other studies of early therapy in infants [7, 16] and from a cross-sec-
tional study in older children [12]. Measurement of HIV-1 RNA AUC over the first year of
cART provided a more quantitative estimate of exposure to HIV-1 replication at early time
points after cART initiation than previously reported, allowing us to discern a highly signifi-
cant association between PBMC HIV-1 DNA levels at 1 year and plasma RNA AUC over the
Early cART Limits Cell-Associated HIV-1 DNA
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first year of treatment. Thus, our longitudinal studies more precisely define the relationship
between exposure to HIV-1 replication in early primary infant infection and PBMC HIV-1
DNA levels after one year of treatment.
The number of participants included in the study (N = 30) is relatively small, but it is similar
to the number of participants in recently reported studies [7, 16] and was sufficient for the orig-
inal aims of demonstrating within subject treatment effects. The power to detect changes in
HIV-1 DNA levels within participants exceeded 95% for both the entire group (N = 30) and
the subgroup of responders (N = 21). The power to detect a difference in tests of association
with plasma HIV-1 RNA was 82%, while the power to detect the differences in the rates of
decline between ET and LT groups was reduced to 68% overall and 47% in responders. As
noted, only limited data are available on HIV-1 DNA levels in children who have achieved
Fig 2. Estimation of PBMCHIV-1 DNA Decline. a) Estimation of PBMCHIV-1 DNA Decline in All Children over the First Year of cART. ET (closed
circle and solid line) and LT children (open circle and dashed line) experienced a significant decline in PBMC HIV-1 DNA after one year of cART (-1.04±0.11
log10 DNA copies per million PBMC, p<0.001 in ET and -0.74 ±0.13 log10 DNA copies per million PBMC, p<0.001 in LT). b) Estimation of PBMCHIV-1 DNA
Decline in Children with Controlled HIV-1 Replication. ET (closed circle and solid line) and LT children (open circle and dashed line) experienced a
marked decline in PBMCHIV-1 DNA levels in the first year of cART (-1.03±0.12 log10, p<0.001 in ET and -0.82±0.16 log10, p<0.001 in LT), but the rates of
decline did not differ significantly between ET and LT (p = 0.3). Similarly, in years 1 through 4 of cART, PBMCHIV-1 DNA levels continued to decline
significantly in both the ET (p<0.001) and LT groups (p<0.001), but the decline slopes were not statistically significantly different between the groups.
doi:10.1371/journal.pone.0154391.g002
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viral suppression after early cART and who have available repository for longitudinal studies.
These results will be useful for estimating effect sizes necessary for planning future studies
characterizing the persistence of HIV-1 cellular reservoirs.
While cART reduced circulating PBMC HIV-1 DNA levels, HIV-1 DNA remained detect-
able in all children followed through 4 years of age. An important question is whether detectable
HIV-1 DNA represents replication-competent virus capable of initiating HIV-1 replication in
the absence of cART. PBMC HIV-1 DNA levels are estimated to be at least 100–150 times
higher than levels of inducible provirus measured using viral outgrowth assays [16, 19]. While
we did not directly measure the latent reservoir in this study, prior work has documented that
early cART does not eliminate the latent reservoir [20] in infants. Moreover, the magnitude of
reduction in latent reservoir size following early cART appears to be lower than the minimum
3–4 log10 reduction in reservoir size estimated in a recent model to predict periods of treatment-
free remission [21]. Indeed, plasma HIV-1 RNA is readily detected within weeks of treatment
discontinuation following early cART [22] and increases in circulating HIV-1 DNA levels have
been reported following virologic rebound [7]. Thus, treatment discontinuation is not currently
recommended for early-treated children outside of highly monitored research protocols.
Our data indicating a significant relationship between time to control of HIV-1 replication
and residual HIV-1 reservoirs suggest that even earlier cART initiation may reduce long-lived
HIV-1 reservoirs sufficiently to allow clinically significant periods of remission off treatment.
The recently described case of the “Mississippi Baby” in which cART initiated within 30 hours
of birth likely resulted in sufficient reduction of HIV-1 reservoirs to allow 27 months of remis-
sion off cART [23], provides additional support for this concept. Clinical trials of very early
therapy (i.e., initiated within 48 hours of birth) are underway to evaluate whether this approach
could provide a pathway for achieving long-term HIV-1 remission off antiretroviral therapy in
children. These clinical trials will also provide an opportunity to further explore cell-associated
HIV-1 DNA levels on cART as well as the relationship between measures of HIV-1 persistence
and the potential for remission off therapy.
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